Cambridge Epigenetics

The IP stems from the work of Anjana Rao, who identified 5-hydroxymethylcytosine (5hmC) as a cancer diagnostic biomarker.

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

The company was founded as a spinout of the University of Cambridge to commercialize an epigenetic sequencing technique called oxidative bisulfite sequencing.

Lab7 Systems has released a beta version of its next-generation sequencing data workflow management software platform, available for download to early-access users from the company's website. The company is planning updates to the software every four to six weeks.

This article was originally published May 17.
Startup firm Cambridge Epigenetix plans to commercialize an epigenetic sequencing technique, with the launch of its first product — called TrueMethyl — expected in August.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.